NICE is unable to make a recommendation about the use in the NHS of ramucirumab with erlotinib for untreated epidermal growth factor receptor (EGFR)-positive metastatic non-small-cell lung cancer because Eli Lilly and Company Limited did not provide an evidence submission. The company has confirmed that it does not intend to make a submission for the appraisal because the technology is unlikely to be a cost‑effective use of NHS resources.


If NHS organisations wish to consider ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer, they should follow the advice on rational local decision making in the NHS Constitution for England and the NHS Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012. This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-3725-7

  • National Institute for Health and Care Excellence (NICE)